KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Cash from Financing Activities (2016 - 2025)

Cvs Health (CVS) has disclosed Cash from Financing Activities for 17 consecutive years, with -$2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 571.46% year-over-year to -$2.0 billion, compared with a TTM value of -$4.9 billion through Dec 2025, down 335.24%, and an annual FY2025 reading of -$4.9 billion, down 335.24% over the prior year.
  • Cash from Financing Activities was -$2.0 billion for Q4 2025 at Cvs Health, down from -$1.4 billion in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $3.6 billion in Q2 2023 and bottomed at -$3.3 billion in Q2 2021.
  • Average Cash from Financing Activities over 5 years is -$1.3 billion, with a median of -$2.0 billion recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 247.34% in 2023, then crashed 571.46% in 2025.
  • Year by year, Cash from Financing Activities stood at -$2.9 billion in 2021, then increased by 24.95% to -$2.2 billion in 2022, then skyrocketed by 55.56% to -$972.0 million in 2023, then surged by 144.34% to $431.0 million in 2024, then plummeted by 571.46% to -$2.0 billion in 2025.
  • Business Quant data shows Cash from Financing Activities for CVS at -$2.0 billion in Q4 2025, -$1.4 billion in Q3 2025, and $806.0 million in Q2 2025.